Delivery Order SPE2DB22D2206-SPE2DB25FJF56
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $36,593.17. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract does not utilize a set-aside designation and falls under the company's existing Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,328.29 to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Actemra 162 mg/0.9 ml syringes. This firm fixed-price delivery order is scheduled for completion by July 31, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award was made through open competition with no set-aside designation, reflecting the contractor's demonstrated capability to meet federal pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $2,158.38 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes. The contract, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX),...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 ml syringes, with a contract ceiling value of $12,196.90. This firm fixed-price delivery order, issued on August 1, 2025, carries an ultimate completion date of August 4, 2025, and represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $11,196.02 to AmerisourceBergen Drug Corp for 4,568,895,450 units of Actemra 400 mg/20 mL vials on July 25, 2025, with an ultimate completion date of July 28, 2025. The contract utilizes firm fixed pricing with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a competitive award under AmerisourceBergen's existing Indefinite...
- AmerisourceBergen Drug Corp was awarded a delivery order contract by the Defense Logistics Agency (DLA) on July 26, 2025, for the supply of ACTEMRA 162 mg/0.9 mL syringes valued at $5,945.97 with a firm fixed price structure. The contract specifies a completion date of July 28, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This is an unrestricted, competitively awarded delivery order with no set-aside designation. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $7,194.60 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes on August 4, 2025, with an ultimate completion date of August 5, 2025. This firm fixed price delivery order, which was competitively awarded without set-aside designation, will be performed at the company's corporate headquarters in Conshohocken, Pennsylvania. Actemra is a biologic immunosuppressant medication commonly used in the treatment...
- The Defense Logistics Agency awarded a delivery order valued at $23,388.90 to AmerisourceBergen Drug Corp for Actemra 162 mg/0.9 mL syringes with a completion date of July 22, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is classified as a child contract under a larger vehicle. The pharmaceutical product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery...
- The Defense Logistics Agency (DLA) awarded a $13,171.30 delivery order to AmerisourceBergen Drug Corp for 4,568,832,740 units of Actemra 400 mg/20 mL vials on July 18, 2025, with an ultimate completion date of July 21, 2025. This is a firm fixed-price, non-set-aside contract with place of performance in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,600.42 to AmerisourceBergen Drug Corp for the supply of ACTEMRA 162 mg/0.9 mL syringes on July 28, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and specifies performance at AmerisourceBergen's Conshohocken, Pennsylvania location, with an ultimate completion date of July 29, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJF56Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Actemra 162 mg/0.9 mL syringes, with a ceiling value of $23,369.56 and a firm fixed price structure. The delivery order is non-set-aside and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vendor agreement running through December 2026. Performance is scheduled for completion by August 5, 2025, at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order supports the Defense Health Agency and military healthcare systems' pharmaceutical supply needs through AmerisourceBergen's comprehensive global pharmaceutical support vehicle. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen leverages its extensive distribution capabilities to supply specialty medications and medical supplies to support military healthcare programs worldwide. The Actemra supply under this delivery order contributes to the company's established portfolio of pharmaceutical deliveries across multiple therapeutic domains to federal customers, continuing its role as a competitive prime vendor within DLA's pharmaceutical procurement strategy.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $23.4k | 8/4/25 |